Edwards Lifesciences Co. (NYSE:EW) Shares Bought by RDA Financial Network

RDA Financial Network grew its holdings in Edwards Lifesciences Co. (NYSE:EW) by 7.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 33,247 shares of the medical research company’s stock after purchasing an additional 2,417 shares during the quarter. RDA Financial Network’s holdings in Edwards Lifesciences were worth $2,194,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in EW. Crewe Advisors LLC acquired a new position in shares of Edwards Lifesciences in the first quarter worth $28,000. First Community Trust NA purchased a new stake in Edwards Lifesciences during the 2nd quarter worth about $29,000. Riverview Trust Co acquired a new stake in Edwards Lifesciences in the 1st quarter valued at about $34,000. Webster Bank N. A. purchased a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $39,000. Finally, Peoples Bank KS acquired a new position in shares of Edwards Lifesciences during the third quarter worth about $40,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total value of $333,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,133,916.72. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,250 shares of company stock valued at $751,688 over the last quarter. Company insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on EW shares. JPMorgan Chase & Co. downgraded shares of Edwards Lifesciences from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $105.00 to $72.00 in a research note on Thursday, July 25th. Oppenheimer reissued an “outperform” rating and issued a $90.00 target price on shares of Edwards Lifesciences in a report on Thursday, September 12th. TD Cowen downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price target for the stock from $100.00 to $70.00 in a report on Thursday, July 25th. Truist Financial dropped their price objective on Edwards Lifesciences from $82.00 to $71.00 and set a “hold” rating on the stock in a report on Friday, September 13th. Finally, Wolfe Research upgraded Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research note on Monday, July 29th. Seventeen equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $75.77.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock traded down $0.60 during trading hours on Tuesday, reaching $69.03. 2,677,985 shares of the stock were exchanged, compared to its average volume of 4,573,907. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The stock has a market cap of $41.60 billion, a P/E ratio of 29.72, a P/E/G ratio of 2.83 and a beta of 1.13. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The firm’s 50 day moving average is $67.31 and its 200 day moving average is $79.79.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The firm had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. During the same quarter last year, the firm earned $0.66 earnings per share. The firm’s revenue was up 6.7% compared to the same quarter last year. Analysts predict that Edwards Lifesciences Co. will post 2.71 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.